5

Sony Exhibits at the World's Largest International Conference on Accessibility "CSUN Assistive Technology Conference 2022"

Retrieved on: 
Monday, March 14, 2022
DualShock, Sony α, Music, 5, Hearing, Intention, Name, Sony, Communication, Smartphone, View, Conference, Ear, Multimedia, Microsoft, Creativity, BRAVIA, Color, SIE Worldwide Studios, Vibration, Human, SONY, Technology, Environment, Intelligence, Google, CSUN Assistive Technology Conference, PlayStation, Video game, Mobile phone, Video game console

Sony applies technology to incorporate accessibility into our products and services to strive for a future where everyone shares the moment, overcoming their limitations.

Key Points: 
  • Sony applies technology to incorporate accessibility into our products and services to strive for a future where everyone shares the moment, overcoming their limitations.
  • Sony Exhibit at CSUN Assistive Technology Conference, World's Largest International Event on Accessibility, March 14-18
    By setting accessibility functions that assist sight, hearing, and operation, users can enjoy watching TV more easily.
  • PlayStation strives to create a gaming experience without barriers that fits the needs of players of all abilities .
  • PlayStation Studios also creates a variety of industrydefining software titles with an array of vision, hearing and motor accessibility settings.

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

Retrieved on: 
Thursday, March 3, 2022
IDO, Audit committee, MBA, IO, PD-L1, Willamette University, 5, Forward-looking statement, Securities Exchange Act of 1934, Board of directors, Therapy, Genentech, Board, Company, Cancer, Economics, Audit, Securities Act of 1933, CEO, Golden Gate University, Amgen, History, BA, IBM, Monmouthshire, Nasdaq, GLOBE, Management, Thoratec, Chiron

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors.

Key Points: 
  • NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors.
  • Mr. Smith, a veteran biotech executive with over 30 years of experience in executive and financial leadership, will serve on the Audit Committee of the Board.
  • "David is a welcome addition to the IO Biotech Board, bringing substantial experience in guiding multiple biotech companies through all stages of development as well as deep expertise in finance and corporate governance," said Mai-Britt Zocca, Ph.D., CEO and founder of IO Biotech.
  • I am delighted to join the Board at this exciting time in IO Biotechs evolution, said Mr. Smith.

INFINOX Clients in Southeast Asia Now Have Access to MetaTrader 5 Software

Retrieved on: 
Monday, February 28, 2022
Budget, Atmosphere, Technology, MetaTrader 4, Insurance, Industry, 5, Software, Policy

With that in mind, leading online trading services provider INFINOX recently announced that the MetaTrader 5 platform and software, known and trusted by millions of traders around the world, will now be available to all of its clients in Southeast Asia, as well as in other regions of the globe.

Key Points: 
  • With that in mind, leading online trading services provider INFINOX recently announced that the MetaTrader 5 platform and software, known and trusted by millions of traders around the world, will now be available to all of its clients in Southeast Asia, as well as in other regions of the globe.
  • MetaTrader 5, or MT5, is the latest edition of the trading software provided by the renowned company MetaQuotes.
  • Users of this platform have access to a versatile range of assets, including stocks, commodities, futures, forex, equities and more.
  • Operating since 2009, INFINOX today is a veteran name in the online trading sector, trusted by many around the globe.

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS

Retrieved on: 
Saturday, February 26, 2022
Risk, Orphan, Annual report, Virus, COVID-19, Therapy, Cytokine, TSLP, EPS, Immunoglobulin E, Biomarker, Asthma, Form 10-K, Solution, Research, Chronic obstructive pulmonary disease, Genetics, Board of directors, Allergy, Growth, 5, Inflammation, Public expenditure, Eosinophilic, Safety, Disease, EOE, Adoption, Biotechnology, Dow Jones Industrial Average, Priority review, Phenotype, Sinusitis, Eosinophilic esophagitis, AstraZeneca, Population, Polyp (medicine), Barron's, Confidentiality, Forward-looking statement, Patient, Form 8-K, Movement, 100 Best Workplaces in Europe, Collaboration, Eosinophil, Biology, Clinical trial, BeiGene, Acquisition, News, Pandemic, FDA, Allergen, Marketing, Technology, Patent, Pharmaceutical industry

Globally, there are approximately 2.5 million patients with severe asthma who are uncontrolled or biologic eligible, with approximately 1.3 million in the U.S.

Key Points: 
  • Globally, there are approximately 2.5 million patients with severe asthma who are uncontrolled or biologic eligible, with approximately 1.3 million in the U.S.
  • Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.13-18 Uncontrolled asthma occurs when symptoms persist despite treatment.
  • Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid-single-digit royalty toAmgen.
  • Amgenis committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

Polestar 5 to be Faster, Lighter and More Dynamic Thanks to Brand-New UK-Developed Bonded Aluminum Platform

Retrieved on: 
Tuesday, February 15, 2022
Engineering, Automotive, General Automotive, Automotive Manufacturing, Other Automotive, Manufacturing, Prospectus, YouTube, Carbon, Securities Act of 1933, Private Securities Litigation Reform Act, 2, Technology, GT, Person, Acquisition, Engineering, Geely, COVID-19, LLC, Concept, Company, Aluminium, SEC, 5, Terminology, Intention, Cell, Sale, Industry, Volvo, Heart, The Gores Group, Risk, Climate, HP, Nasdaq, THE, Safety, Car, Stiffness, Name, Volvo Cars, WLTP, Business, Business architecture, CRIMINAL, 1, Forward-looking statement, Semiconductor, Solution, Formula One, SUV, Proxy, EV, Press release, Failure, Adjustment, Attention, Renewable energy, Bookkeeping, Risk management, Security (finance), Polestar

Polestar, the Swedish premium electric performance car maker, has confirmed that the forthcoming Polestar 5 electric performance 4-door GT will feature a brand-new, bespoke, bonded aluminum platform.

Key Points: 
  • Polestar, the Swedish premium electric performance car maker, has confirmed that the forthcoming Polestar 5 electric performance 4-door GT will feature a brand-new, bespoke, bonded aluminum platform.
  • The new bonded aluminum platform will also help drive faster product introduction, high quality and platform rigidity.
  • By further developing this technology for Polestars first in-house platform, the 4-door Polestar 5 is being designed with torsional rigidity superior to that of a traditional two-seat sports- or supercar.
  • This architecture delivers outstanding dynamic and safety attributes, with low investment technology applicable to high production volumes.

AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES

Retrieved on: 
Thursday, February 3, 2022
Growth, Public expenditure, Safety, Government, Forward-looking statement, Patient, Barron's, Therapy, Neurodegeneration, NASDAQ, BeiGene, Proteolysis targeting chimera, Clinical trial, Biotechnology, Fortune, Pandemic, Form 8-K, Technology, Patent, Adoption, Board of directors, COVID-19, Apremilast, Research, Cancer, Marketing, Confidentiality, Partnership, AMGN, Program, Disease, U.S. Securities and Exchange Commission, Drug discovery, Dow Jones Industrial Average, Acquisition, News, 5, Movement, 100 Best Workplaces in Europe, Form 10-K, LinkedIn, Proximity, Protein, Biology, Security (finance), Genetics, Solution, EPS, Annual report, Pharmaceutical industry, Fine chemical, Amgen

THOUSAND OAKS, Calif.andSAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets.

Key Points: 
  • THOUSAND OAKS, Calif.andSAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets.
  • The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules.
  • The partnership will focus on expanding targeted protein degradation opportunities through discovery of previously unrecognized molecular glues or monovalent degraders.
  • This collaboration incorporates Plexium's comprehensive targeted protein degradation platform, powered by a proprietary high-throughput cell-based screening technology that enables the discovery of novel molecular glue therapies.

FOX News Channel Makes Cable News History as the First Network to Rank Number One for 20 Consecutive Years

Retrieved on: 
Tuesday, February 1, 2022
TV and Radio, General Entertainment, Entertainment, Online, Growth, Story, News, The Tonight Show, NEWS, MSNBC, VS, TOP, The Ingraham Angle, HGTV, Nielsen Media Research, The Rachel Maddow Show, Fox News, Breaking news, Unfiltered, Life, Liberty & Levin, Workweek and weekend, FNC, Fox, One Nation, Program, America Reports, Greg Gutfeld, The Next Revolution, THE, 5, Democrat, FOX, TBS, New Day, Research, Carlson, History, CNN, Media Buzz, Hallmark, Television, Friends, Democracy, The Sundays

Since January 2002, FNC has remained the most-watched cable news network across both dayparts with total viewers and in the 25-54 demographic.

Key Points: 
  • Since January 2002, FNC has remained the most-watched cable news network across both dayparts with total viewers and in the 25-54 demographic.
  • In total day, FNC garnered 1.4 million viewers, 226,000 with the 25-54 demo and 138,000 with the 18-49 demo.
  • Notably, CNN shed more than 80% of its viewers in total day and primetime demo and plummeted across all categories.
  • The number one network in basic cable, FNC has been the most watched television news channel for 20 consecutive years.

Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control

Retrieved on: 
Friday, January 28, 2022
Mobile, Wireless, Technology, Medical Devices, FDA, Diabetes, Other Health, Biotechnology, Pharmaceutical, Health, Consumer Electronics, People, Insulin, CEO, Insulin pump, Food, NASDAQ, AID, Diabetes, Glucose, POD, CGM, Engineering, 5, Eastern Time Zone, Technology, DASH, Wellness, Corporation, G6, Science and technology in Asia, Alternative medicine, U.S. Securities and Exchange Commission, Annual report, Freedom, Company, Health, Automated insulin delivery systems, Paracetamol, Ageing, Smartphone, Regulation of tobacco by the U.S. Food and Drug Administration, Chicago Innovation Awards, FDA, Multimedia, Risk, Security (finance), ID, Medical device, Copper, Pharmaceutical industry, Dexcom

Omnipod 5 is the first tubeless automated insulin delivery (AID) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and a compatible smartphone to automatically adjust insulin and help protect against highs and lows.

Key Points: 
  • Omnipod 5 is the first tubeless automated insulin delivery (AID) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and a compatible smartphone to automatically adjust insulin and help protect against highs and lows.
  • We are incredibly proud of this simple-to-use, elegant system, designed to deliver unmatched freedom and to greatly simplify insulin management and improve glucose control for our users.
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • 2 The Omnipod 5 Automated Insulin Delivery System is comprised of SmartAdjust technology (cleared in K203774), the Omnipod 5 Pod and Omnipod 5 App (cleared in K203768) and the Omnipod 5 SmartBolus Calculator (cleared in K203772).

DOVE LAUNCHES 'AS EARLY AS FIVE' TO ILLUMINATE HOW YOUNG RACE-BASED HAIR DISCRIMINATION STARTS IN ONGOING EFFORT TO PASS THE CROWN ACT IN REMAINING 36 U.S. STATES

Retrieved on: 
Wednesday, January 26, 2022
Workplace, EVP, Hair, Parent, COO, National Urban League, Legislation, Organization, Human, Heart, Recreation, Seventh generation, Anxiety, Bias, Advertising, Health, View, Education, 5, CA, Unilever, Movement, Knorr, School, Leadership, Research, Growth, Man, Natural hair movement, Woman, Dow Jones, DE, CO, Awareness, Magnum, Girls For A Change, CROWN Act (California), Sunlight, OR, Hourglass, Columbidae, NEW, Personal care, Culture, Multimedia, Kenneth and Mamie Clark, Coalition, OMO, Toy, Hunting, Jewellery, Cosmetics, Marketing, Black, Mental illness portrayed in media, Surf, MD, Beauty, Color, Lifebuoy

Through this campaign, Dove continues its mission to raise awareness for CROWN Act legislation and spark urgency among parents, school administrators and advocates to sign The CROWN Act petition at Dove.com/CROWN to make race-based hair discrimination illegal nationwide.

Key Points: 
  • Through this campaign, Dove continues its mission to raise awareness for CROWN Act legislation and spark urgency among parents, school administrators and advocates to sign The CROWN Act petition at Dove.com/CROWN to make race-based hair discrimination illegal nationwide.
  • Dove believes Black women and girls should have the freedom to wear their hair how they choose without the fear of job loss or education.
  • Now, this new body of research illuminates the pervasive nature and deep impact hair discrimination has on Black girls highlighting the horrific multi-generational impact of narrow beauty standards in America.
  • These biases continue to perpetuate unfair scrutiny and discrimination against Black women and girls for wearing hairstyles inherent to our culture.

Information on the outcome of the First Extraordinary General Meeting of Shareholders, and Convening Notice for a reconvened Extraordinary General Meeting of Shareholders

Retrieved on: 
Monday, January 24, 2022
Online, Association, Article, Euroclear, Treasury, 5, Cession, DTCC, Board of directors, Person, THE, Exercise, Record, Nasdaq Stockholm, Nasdaq, CET, First, Union Internationale des Avocats, Proxy, Millicom, SDR, Address, Broadridge Financial Solutions, European Parliament, Ownership, Council, Best-effort delivery, Company, Shareholder, Attention, General Data Protection Regulation, USD, Law, European, Scrutineer, EGM, Board, Security (finance), Auction, Holding company, Mail, Audit, Bank, EU

Beneficial owners who do not vote via their brokers/nominees or do not have a legal proxy are not eligible to vote.

Key Points: 
  • Beneficial owners who do not vote via their brokers/nominees or do not have a legal proxy are not eligible to vote.
  • Online: The Company had sent by post the invitation letter and the Millicom Shareholder Proxy Form needed to vote at the First EGM.
  • The original completed, dated and signed Millicom Shareholder Proxy Form (reconvened EGM) should be mailed to the address provided in the form.
  • Shareholders have the right to ask questions about items on the agenda of the EGM ahead of the meeting.